VCEL
Vericel Corporation35.50
-0.99-2.71%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
FY Q3 '25
Key Stats
Market Cap
1.80BP/E (TTM)
136.54Basic EPS (TTM)
0.26Dividend Yield
0%Recent Filings
8-K
Record Q3 revenue, profit surge
Vericel posted record Q3 revenue of $67.5 million, up from $57.9 million last year, driven by 25% MACI growth to $55.7 million while Burn Care held at $11.8 million. Net income flipped to $5.1 million; operating cash flow hit $22.1 million. Cash sits at $185 million, debt-free. Full-year revenue guide holds at $272-276 million.
10-Q
Q3 FY2025 results
Vericel posted Q3 revenue of $67.5M, up 16.6% y/y from $57.9M, fueled by 24.6% MACI growth to $55.7M and NexoBrid's 37.7% jump to $1.5M, despite Epicel's 14.8% dip; gross margin hit 73.5% from 71.9%. Operating income flipped to $3.5M profit from $2.5M loss, while YTD net loss narrowed to $6.7M from $9.4M on $183.3M revenue (13.3% y/y). Cash swelled to $100.4M, no debt on $150M revolver. MACI Arthro launched Q3. Supply from Israel poses risks.
8-K
Q2 revenue up 20%
Vericel posted Q2 revenue of $63.2 million, up 20% year-over-year, driven by 21% MACI growth to $53.5 million while Burn Care hit $9.8 million. Gross margin jumped over 400 basis points to 74%; adjusted EBITDA soared 112% to $13.4 million. Momentum builds. Guidance holds at low 20% MACI growth and 26% adjusted EBITDA margin.
10-Q
Q2 FY2025 results
Vericel posted Q2 revenue of $63.2M, up 20.1% y/y from $52.7M, fueled by MACI's 21.1% surge to $53.5M while Epicel and NexoBrid grew 11.0% and 51.9%. Gross profit jumped 27.4% to $46.6M as fixed manufacturing costs held steady. Operating loss narrowed to $2.0M from $6.0M y/y, yet SG&A climbed 18.8% on headcount and marketing; net loss shrank to $0.6M or $(0.01) per share. Cash hit $80.5M with $36.3M short-term investments; $150M revolver fully available, no borrowings. Operating cash flow slowed to $14.8M YTD. Capex consumed $22.3M for Burlington facility. Supply from Israel poses risks.
10-Q
Q1 FY2025 results
Vericel posted Q1 revenue of $52.6M, up 2.6% y/y from $51.3M, with MACI surging 15.2% to $46.3M on volume and price while Epicel dropped 53.5% to $5.0M and NexoBrid tripled to $1.3M. Gross profit climbed 2.6% to $36.3M, but SG&A ballooned 21.5% to $41.8M on headcount and marketing, driving operating loss wider to $(12.8M) from $(5.5M) and net loss to $(11.2M) or $(0.23)/share versus $(3.9M) or $(0.08)/share—net trails operating due to $11.5M stock-based comp. Cash flow from operations held at $6.6M, with $73.5M cash plus $82.8M investments and $150M revolver fully available (no draws). Capex hit $14.2M for Burlington facility. Solid liquidity endures. FDA disruptions could slow approvals.
BRTX
BioRestorative Therapies, Inc.
1.08-0.03
CELU
Celularity Inc.
1.35-0.05
CVM
Cel-Sci Corporation
5.90-0.10
LGVN
Longeveron Inc.
0.55+0.00
MDWD
MediWound Ltd.
18.77-0.28
MESO
Mesoblast Limited
18.29+0.58
RCEL
Avita Medical, Inc.
3.33-0.07
VERA
Vera Therapeutics, Inc.
48.30-0.91
VICP
Vicapsys Life Sciences, Inc.
1.50+0.00
VRTX
Vertex Pharmaceuticals Incorpor
454.96-0.75